Trevi Prurigo Nodularis
We know these are challenging times and venturing out can be especially stressful. We want you to know that at CRCC we have implemented every safety measure possible to keep you safe and prevent the spread of Covid-19. Patient areas are continually disinfected, social distancing is enforced in our lobby, and all staff wear masks/gloves throughout the day. If you arrive for your appointment and wish to wear a mask, we will provide one for you as well.
About Prurigo Nodularis
Prurigo Nodularis is a skin disease characterized by multiple, intensely itchy skin eruptions in symmetrically distributed areas of the extremities. The main symptom is prolonged, repetitive, and uncontrollable rubbing, scratching, and uncontrollable itching which leads to eroding papules and nodules on the skin. It is difficult to treat and entails a high disease burden.
About the Study
52-week study comparing oral nalbuphine to placebo.
What Should I Expect?
- The first 14 weeks of the study are blinded and then all patients get the active drug
- Office visits vary from weekly to monthly
- There is blood work and EKGs throughout the study
- Compensated for time & travel
If you are interested in participating in one of these studies, please provide your contact information below. If you are a qualified candidate, a representative from our research department will be in touch with you.